CLINICAL SIGNIFICANCE OF PROBIOTICS AND PREBIOTICS IN GASTRIC DISEASES

Abstract

Gastric diseases such as chronic gastritis, peptic ulcer disease, functional 
dyspepsia, and gastroesophageal reflux disease represent some of the most common 
gastrointestinal disorders worldwide, affecting more than 40% of the global 
population. This study aimed to evaluate the clinical efficacy of probiotics and 
prebiotics in the management of gastric diseases. A prospective clinical observation 
was conducted in two regional hospitals in Uzbekistan from 2024 to 2025, involving 
60 patients divided into three groups: standard pharmacological therapy only, therapy 
plus probiotics, and therapy plus a combination of probiotics and prebiotics. Clinical 
indicators, including symptom resolution time, recurrence rate within six months, 
antibiotic-associated diarrhea, and patient satisfaction, were assessed. The results 
demonstrated that both probiotics and prebiotics improved clinical outcomes, with the 
combined therapy showing the most significant benefits, including shorter symptom 
resolution time (5.6 ± 1.3 days), lower recurrence (8%), and higher patient satisfaction 
(92%). These findings suggest that integrating probiotics and prebiotics into standard 
treatment regimens may enhance recovery, reduce complications, and improve patient
reported outcomes. Nevertheless, larger multicenter studies are needed to validate these 
results and strengthen clinical recommendations.